Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)
Year: 2026
Type: article
Study design: Study Protocol
Abstract: BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with most patients diagnosed at an advanced stage. Atezolizumab plus bevacizumab is a current standard first-line therapy; however, outcomes are strongly influenced by underlying cirrhosis and clinically significant portal hypertension (CSPH). Complications such as ascites and variceal bleeding may limit treatment continuation, particularly as bevacizumab increases bleeding risk. Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal pressure and may improve outcomes, but its role in patients receiving immunoncology-based systemic therapy remains unclear. METHODS: NISTIPS TRITICC-4 is a prospective, multicentre, non-interventional cohort study conducted at up to 25 centers in Germany. A total of 350 adult patients with cirrhosis and unresectable or metastatic HCC receiving first-line atezolizumab plus bevacizumab will be enrolled. Patients are allocated to two cohorts: TIPS in situ plus atezolizumab and bevacizumab or atezolizumab plus bevacizumab alone, according to routine clinical practice.The primary endpoint is time to deterioration of liver function (TTDL), defined as persistent worsening of liver parameters for >4 weeks. Secondary endpoints include overall survival, time on treatment, overall response rate, time to new extrahepatic lesions or death, and safety with focus on bleeding and TIPS-related complications.Time-to-event endpoints will be analyzed using Kaplan-Meier methods and Cox models. Propensity score matching will be applied to adjust for confounding. Analyses are exploratory. DISCUSSION: This study will provide real-world evidence on the impact of TIPS in HCC patients receiving atezolizumab plus bevacizumab and may support more individualized management strategies in this high-risk population. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT07365930.
Source: Future Oncology
Authors: Carolin Angendohr, Christian Weigel, Anselm Kunstein, Markus Joerdens, Thorsten Goetze, Salah-Eddin Al-Batran, Bianca Zäpf, Maria Gonzalez-Carmona, Cennet Sahin, Marie-Luise Berres, Friedrich Foerster, Najib Ben Khaled, Christine Koch, Arne Kandulski, Henning Wege, Jonel Trebicka, Leonie S. Jochheim, Michael T. Dill, Christoph Springfeld, Severin Daum, Christoph Treese, Ursula Ehmer, Tom Luedde, Johannes Bode, Christoph Roderburg
Institutions: Düsseldorf University Hospital, Institute of Clinical Cancer Research, University Hospital Bonn, Universitätsklinikum Aachen, University Medical Center of the Johannes Gutenberg University Mainz, LMU Klinikum, Ludwig-Maximilians-Universität München, University Hospital Frankfurt, University Hospital Regensburg, Klinikum Esslingen, University Hospital Münster, Essen University Hospital, Heidelberg University, Charité – Universitätsmedizin Berlin, TUM Klinikum, Technical University of Munich
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7223101032
